RxDoctor Payments DataLook up a doctor →

Andrzej Jasek, MD

Rheumatology · Rockford, ILNPI 1578636692

Payments from drug & device makers

$300,916in general payments, 2019–2025

Across 210 payments — averaging $1432.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$283K
  • Eli Lilly$17K
  • Amgen$397
  • Lilly USA, LLC$203
  • GSK$180
  • Janssen Scientific Affairs, LLC$137
  • plus $507 from 7 others
$3,150in research payments, 2019–2025

Across 1 payment — averaging $3150.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$3K

What the payments were for

  • Consulting fees$402%
  • Food & beverage$2,50795%
  • Education$913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$300,916 in reported general payments places this provider in the 95th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,464,327
Medicare patients
724
Services billed
192,676

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept77$572,478
RinvoqUpadacitinib80$510,474
Humira(Cf) PenAdalimumab72$488,313
EnbrelEtanercept37$268,017
Teriparatide66$207,622
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5026$162,637
ForteoTeriparatide15$62,743
MethotrexateMethotrexate Sodium669$17,139
Leflunomide332$15,451
SavellaMilnacipran Hcl22$13,748
Hydroxychloroquine Sulfate371$12,229
Mycophenolate Mofetil85$7,534
Pregabalin80$6,755
Azathioprine90$6,080
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen291$5,938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Savella$282,697$524,222102 claims
AmgenEnbrel$397$268,01737 claims
Lilly USA, LLCForteo$203$62,74315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 287 rheumatology providers in Illinois.

Other rheumatology in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →